招股书 · 2026-01-09

Post-IPO Equity Incentive Dilution: Calculating the Impact from Prospectus Disclosures

The first 12 months post-listing often reveal a tension that was papered over in the prospectus: the real cost of equity incentives. For Hong Kong-listed issuers, the dilution impact from share option schemes and restricted share award plans is not always linear, nor is it fully captured by a single ratio in the listing document. A growing number of Main Board and GEM applicants in 2024 and 2025 have disclosed post-IPO equity incentive pools exceeding 10% of the enlarged issued share capital, with some reaching 15% to 20% when combining pre-IPO grants, the post-IPO scheme mandate, and potential refreshment triggers. The HKEX’s Listing Decision HKEX-LD136-1 (2024 update) and the SFC’s revised Code on Takeovers and Mergers (effective 1 January 2025) have sharpened the focus on how these dilutive instruments interact with control thresholds and public float requirements. For analysts and IPO project teams, the prospectus remains the primary source document for modelling this dilution — but only if the reader knows exactly which sections to cross-reference and how to weight the disclosed assumptions.

The Dilution Mechanics Embedded in the Prospectus

The Two-Stage Calculation: Pre-IPO Grants vs. Post-IPO Scheme Mandate

Every Hong Kong IPO prospectus must disclose two distinct equity incentive pools under HKEX Listing Rule 17.02 (for share option schemes) and Rule 17.12 (for share award schemes). The first pool comprises grants made prior to the listing date, typically under a pre-IPO share option plan or restricted share unit (RSU) plan. The second pool is the post-IPO scheme mandate limit, which the issuer seeks shareholder approval for at the time of listing. The combined dilution from these two pools is the starting point for any model.

Take the example of a 2024 Main Board applicant in the healthcare sector: the prospectus disclosed 48,000,000 pre-IPO options outstanding, representing 12.0% of the 400,000,000 shares in issue immediately before listing. The post-IPO scheme mandate was set at 40,000,000 shares, or 10.0% of the enlarged issued share capital of 400,000,000. The total potential dilution, if all options vested and were exercised, was 88,000,000 shares, or 22.0% of the pre-listing share count. However, the actual dilutive effect on public shareholders is lower if the exercise price exceeds the IPO price, meaning the options are out-of-the-money at listing — a scenario that the prospectus’s sensitivity table (typically in the “Dilution” section under “Share Option Schemes”) should explicitly address.

The Dilution Waterfall: From Grant to Vesting to Exercise

The prospectus rarely presents a single dilution figure. Instead, the dilution impact evolves through a three-stage waterfall:

Grant stage: The board approves the number of shares subject to options or awards. This creates a contingent liability but does not immediately dilute earnings per share (EPS) under HKAS 33. The prospectus’s “Earnings Per Share” note will show basic and diluted EPS, with the diluted figure incorporating the weighted-average number of dilutive potential ordinary shares from pre-IPO grants.
Vesting stage: As conditions are satisfied, the shares become exercisable. The prospectus’s “Share Option Scheme” note will disclose the vesting schedule, typically in tranches over 3 to 5 years. The dilutive impact at this stage is captured in the diluted EPS calculation, but only if the exercise price is below the average market price for the period.
Exercise stage: Upon exercise, new shares are issued, increasing the total share count and reducing EPS for the next reporting period. The prospectus’s “Share Capital” note will show the movement in issued shares, but the dilutive effect is only fully realised in the post-listing financial statements.

For analysts, the critical data point is the number of shares that would be issued if all in-the-money options were exercised at the IPO date. This is found in the prospectus’s “Dilution” table, which must disclose the maximum dilution as a percentage of the enlarged issued share capital. The HKEX’s Listing Decision HKEX-LD136-1 (2024 update) clarified that this table must include a sensitivity analysis showing dilution at three price scenarios: the IPO price, a 20% discount, and a 20% premium.

Cross-Referencing the Prospectus’s Dilution Disclosures

The prospectus’s “Share Option Schemes” section is the primary source for the scheme mandate limit, the number of options granted, the exercise price, and the vesting period. Under Listing Rule 17.02, the issuer must disclose the total number of shares available for grant under the scheme, expressed as a percentage of the issued share capital. Under Rule 17.12, for share award schemes, the issuer must disclose the maximum number of shares that may be awarded, the purchase price (if any), and the funding source.

A 2025 GEM IPO in the technology sector disclosed a post-IPO scheme mandate of 25,000,000 shares, representing 10.0% of the 250,000,000 shares in issue immediately after listing. The prospectus also disclosed that 18,000,000 pre-IPO options had been granted at an exercise price of HKD 1.50, compared to the IPO price of HKD 2.00. The sensitivity table showed that if the market price fell to HKD 1.50, the options would be at-the-money, resulting in maximum dilution of 7.2% from the pre-IPO grants plus 10.0% from the post-IPO mandate, totalling 17.2%. If the market price rose to HKD 2.40, the options would be in-the-money, and the dilution from the pre-IPO grants would increase to 7.2% (the same number of shares, but now more valuable).

The “Dilution” Section: The SFC’s Revised Takeovers Code Impact

The SFC’s revised Code on Takeovers and Mergers, effective 1 January 2025, introduced a new Rule 26.2 that requires any person who, together with persons acting in concert, holds 30% or more of the voting rights of a company to make a mandatory general offer. This rule directly impacts equity incentive schemes because the exercise of options or vesting of awards can push a shareholder’s holding across the 30% threshold. The prospectus must now include a statement on whether any pre-IPO grantee or post-IPO scheme participant could, upon exercise, trigger a mandatory offer obligation.

For example, a 2025 Main Board IPO in the consumer goods sector disclosed that the founder and CEO held 28.5% of the pre-listing shares and had been granted 5,000,000 options under the post-IPO scheme. If all options were exercised, the founder’s holding would increase to 31.2%, triggering a mandatory general offer under the Takeovers Code. The prospectus included a waiver application to the SFC, which was granted on the condition that the founder would not exercise the options until the scheme mandate was refreshed or reduced. This disclosure is found in the “Dilution” section, under a sub-heading titled “Impact on Shareholding Structure.”

Modelling the Dilution Trajectory Post-Listing

The Three-Year Vesting Cliff: How Dilution Compounds Over Time

The dilutive impact of equity incentives is not a one-time event. It compounds over the vesting period, typically 3 to 5 years. The prospectus’s “Share Option Scheme” note will disclose the vesting schedule, which often includes a one-year cliff followed by monthly or quarterly vesting. For analysts, the key metric is the annualised dilution rate, calculated as the number of shares vesting in a given year divided by the weighted-average number of shares outstanding.

A 2024 Main Board IPO in the fintech sector disclosed a vesting schedule of 25% at the first anniversary, 25% at the second anniversary, and 50% at the third anniversary. The total pre-IPO grants were 20,000,000 shares, representing 8.0% of the 250,000,000 shares in issue immediately after listing. The annualised dilution for year one was 2.0% (5,000,000 shares / 250,000,000), for year two was 2.0%, and for year three was 4.0%. The post-IPO scheme mandate of 25,000,000 shares (10.0%) would vest over a separate 4-year schedule, adding 2.5% per year. The combined annualised dilution from years one to three was 4.5% to 6.5%, depending on the vesting overlap.

The Public Float Interaction: How Dilution Affects the 25% Threshold

Under HKEX Listing Rule 8.08, a Main Board issuer must maintain a minimum public float of 25% (or such higher percentage as the Exchange may determine). The exercise of options or vesting of awards can reduce the public float percentage if the grantees are not public shareholders (e.g., if the options are held by the founder or management). The prospectus must disclose the public float immediately after listing and the impact of the equity incentive scheme on that float.

A 2025 GEM IPO in the biotech sector disclosed a public float of 30.0% immediately after listing. The post-IPO scheme mandate of 15,000,000 shares, representing 10.0% of the 150,000,000 shares in issue, was reserved for management and employees. If all 15,000,000 shares were issued to non-public grantees, the public float would drop to 27.3% (45,000,000 public shares / 165,000,000 total shares), still above the 25% threshold. However, if the issuer also had pre-IPO options outstanding that were exercised by non-public grantees, the combined dilution could push the public float below 25%. The prospectus included a sensitivity table showing the public float at three exercise scenarios: 0%, 50%, and 100% exercise of all options and awards.

The Prospectus as a Dilution Modelling Tool: Key Data Points

The Sensitivity Table: Price Scenarios and Dilution Outcomes

The most useful single table in the prospectus for dilution modelling is the sensitivity table, typically found in the “Dilution” section or the “Share Option Schemes” section. This table shows the number of shares that would be issued and the dilution percentage at three price scenarios: the IPO price, a 20% discount, and a 20% premium. The HKEX’s Listing Decision HKEX-LD136-1 (2024 update) requires this table to be presented in a standardised format, with columns for the exercise price, the number of options in-the-money, the number of shares issuable, and the dilution percentage.

For a 2025 Main Board IPO in the energy sector, the sensitivity table showed:

At IPO price of HKD 5.00: 12,000,000 options in-the-money, 12,000,000 shares issuable, dilution of 4.8%.
At HKD 4.00 (20% discount): 8,000,000 options in-the-money, 8,000,000 shares issuable, dilution of 3.2%.
At HKD 6.00 (20% premium): 15,000,000 options in-the-money, 15,000,000 shares issuable, dilution of 6.0%.

The table also included a footnote explaining that the number of options in-the-money was calculated using the weighted-average exercise price of HKD 4.50 for pre-IPO grants and HKD 5.50 for post-IPO grants. This level of granularity allows analysts to model the dilution trajectory under different market conditions.

The prospectus’s “Share Capital” note provides the historical and pro forma share capital structure. For modelling purposes, the critical line is the “Shares to be issued upon exercise of share options/awards” under the “Pro forma adjustments” column. This figure is the number of shares that would be issued if all in-the-money options and awards were exercised at the IPO date. The note also discloses the number of shares that have already been issued under pre-IPO grants, which reduces the remaining pool available for future grants.

A 2024 Main Board IPO in the software sector disclosed that 8,000,000 shares had been issued under pre-IPO grants, leaving 12,000,000 shares available under the pre-IPO scheme. The post-IPO scheme mandate was 20,000,000 shares. The pro forma share capital note showed total issued shares of 200,000,000, with a potential additional 32,000,000 shares from the combined equity incentive pools, representing 16.0% dilution. The note also disclosed the weighted-average exercise price of HKD 3.20 for the remaining options, compared to the IPO price of HKD 4.00.

Actionable Takeaways for IPO Project Teams and Analysts

Always cross-reference the “Share Option Schemes” section with the “Dilution” section and the “Share Capital” note to reconcile the total potential dilution from pre-IPO grants and the post-IPO scheme mandate, as each section may use a different base share count.
Model the annualised dilution rate over the vesting period, not just the maximum dilution at grant date, because the EPS impact compounds over 3 to 5 years and the public float threshold may be breached in a single vesting tranche.
Check the sensitivity table for the price scenarios required under HKEX Listing Decision HKEX-LD136-1 (2024 update), and stress-test the dilution at a 20% discount to the IPO price to assess the risk of options being out-of-the-money and the resulting lower dilutive impact.
Verify whether any pre-IPO grantee or post-IPO scheme participant could trigger a mandatory general offer under the SFC’s revised Takeovers Code (effective 1 January 2025) by holding more than 30% voting rights upon exercise, and confirm if a waiver has been obtained.
Use the pro forma share capital note to track the actual number of shares issued under pre-IPO grants, as this reduces the remaining pool and affects the public float calculation immediately after listing.